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ABSTRACT
Oral squamous cell carcinoma (OSCC) is a prevalent cancer with poor 
prognosis. Most OSCC progresses via a non-malignant stage called dysplasia. 
Effective treatment of dysplasia prior to potential malignant transformation 
is an unmet clinical need. To identify markers of early disease, we performed 
RNA sequencing of 19 matched HPV negative patient trios: normal oral mucosa, 
dysplasia and associated OSCC. We performed differential gene expression, 
principal component and correlated gene network analysis using these data. We 
found differences in the immune cell signatures present at different disease stages 
and were able to distinguish early events in pathogenesis, such as upregulation 
of many HOX genes, from later events, such as down-regulation of adherens 
junctions. We herein highlight novel coding and non-coding candidates for 
involvement in oral dysplasia development and malignant transformation, and 
speculate on how our findings may guide further translational research into the 
treatment of oral dysplasia.
INTRODUCTION
Oral squamous cell carcinoma (OSCC) is the 
6th most prevalent cancer worldwide [1] with a 5-year 
survival rate of just 50%. Malignancy drivers for the 
95% of OSCC that is HPV-negative are sorely needed 
as these patients have the worst prognosis. OSCC 
is proposed to occur via a stepwise model whereby 
genetic abnormalities accumulate, resulting in abnormal 
lesions called dysplasia, with higher risk of malignant 
transformation into OSCC than histologically normal 
oral mucosa [2].
To further understand the development and 
malignant transformation of oral dysplasia at the 
cellular level, we have characterised the transcriptomes 
of matched normal oral mucosa, oral dysplasia and 
associated OSCC in 19 patients in unprecedented detail, 
using high coverage strand-specific RNA sequencing 
(RNAseq) that captures information about both coding 
and non-coding RNA (ncRNA > 200bp). Functional 
ncRNAs are now known to be associated with numerous 
diseases, including cancer, where there is evidence of 
their involvement throughout all stages of development 
and progression [3].
Ours is the largest study of matched non-HPV 
infected patient trios, where all dysplasias are associated 
with OSCC, that has been performed to date, and the first 
to include long ncRNAs.
RESULTS
19 HPV-negative patients had RNA extracted and 
sequenced from three samples: normal oral mucosa (N), 
dysplasia (D) and OSCC tumour (T). Figure 1 gives an 
example of a sample trio from a single patient. Clinical 
information, library preparation and sequencing metrics 
are in Supplementary Table S1, Supplementary Table S2 
and Supplementary Results.
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Figure 1: The fixed sections that were H&E stained and annotated to guide RNA extraction from a single patient 
(ID PG063) in this study. Images on the right are magnifications of the areas annotated on the left, to better show histology. Images 
A. and B. pertain to the normal oral mucosa sample, images C. and D. to dysplasia and images E. and F. to tumour. Normal and tumour 
were extracted from the same block whereas dysplasia is from a different block from the same surgery.
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Differentially expressed genes (DEGs)
We performed three pairwise, matched-sample 
comparisons: Normal versus Dysplasia (NvD), Dysplasia 
versus Tumour (DvT) and Normal versus Tumour (NvT). 
Per gene results are given in Supplementary Table S3 and 
numbers of significantly differentially expressed genes 
(DEGs) in Supplementary Table S4. The overlap in DEGs 
for each pairwise comparison is shown in Figure 2. We 
inspected the functional enrichment within the resulting 
subsections, each with a different biological interpretation, 
independently (Figure 2). Assuming the three groups 
represent disease progression i.e. normal epithelium 
become dysplastic, and dysplasia malignantly transforms 
to tumour, we can inspect our DEGs in terms of early and 
late events [2].
Genes associated with the formation  
of dysplasia
Genes that are DE between NvD, but not DvT, are 
dysregulated early, as a cause or consequence of the initial 
development of abnormal, non-malignant cells. This subset 
contains 478 genes, significantly enriched for immune 
response (p.adj: 4.3 × 10−4) and extracellular location 
(p.adj: 5.6 × 10−3). Within these is a subset, 167 genes, DE 
NvD but not NvT (Figure 2). These are still enriched in 
immune response (p.adj: 4.4 × 10−4) but leukocyte (p.adj: 
2.2 × 10−2) and lymphocyte (p.adj: 2.6 × 10−2) activation 
are specifically significant. This is interesting because 
immune responses are not enriched DvT, despite the 
pathologist estimates of infiltrating immune cells being 
higher in tumour than dysplasia in two thirds of our patients 
Figure 2: Venn diagram showing the overlap in lists of differentially expressed genes ascertained per pairwise, 
matched-sample comparison of our dataset. The numeric labels indicate the number of genes in each set. The tables highlight the 
significant (p < 0.05) functional enrichment within each subset according to gene ontology terms (BP: Biological Process, CC: Cellular 
Component and MF: Molecular Function), pathway (PW) analysis using Biocarta, KEGG and Panther, and gene family (GF) enrichment 
according to Panther. NvD: Normal versus Dysplasia. DvT: Dysplasia versus Tumour. NvT: Normal versus Tumour.
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(Supplementary Table S5). To inspect the association 
between immune cell transcriptional signals and pathologist 
estimates, we applied a programme for Estimation of 
STromal and Immune cells in MAlignant Tumours using 
Expression data (ESTIMATE) [4]. This program uses 
immune cell specific gene signatures to score/predict the 
amount of immune cells within the tissue. Results are given 
in Figure 3 and Supplementary Table S5. The pathologist 
immune cell percentage significantly correlates with 
ESTIMATE immune score for both tissue types but both 
the correlation coefficient, r, and level of significance is 
greater for dysplasia versus tumour (dysplasia r:0.72 and 
p:0.0005 versus tumour r:0.49 and p:0.03). This indicates 
that, despite there mostly being more immune cells at the 
tumour stage, the per-immune cell transcriptional signals 
are stronger in dysplasia. We then used the approach 
described in Bindea et al. [5] to inspect the ‘immunome’ i.e. 
which specific types of immune cells are involved during 
different disease stages (NvD compared to DvT). Our 
results (Table 1) indicate that cytotoxic effector immune 
cells infiltrate the dysplasia tissue compared to normal 
tissue, whereas tumour is enriched in inflammatory immune 
cells compared with dysplasia. The average fold changes in 
expression of classical immunohistochemical markers for 
these cell types are also given in Figure 4. To validate these 
findings we then inspected the differential expression of 
immunome genes, NvD and DvT, in an independent cohort 
(dataset GSE30784) of unmatched N (45), D (17) and T 
(167) samples. A significant (Fisher test, p < 0.05) number 
of (i) immature dendritic cell and mast cell genes were DE 
NvD, with an average 23% and 18% increase in expression 
respectively, and (ii) mast cell and macrophages were DE 
DvT with an average 44% decrease and 100% increase 
in expression respectively (Supplementary Table S6). 
Mast cells are cytotoxic effector cells within the oral 
cavity [6]. Despite the unmatched nature of this dataset, 
which negates the ability to account for idiosyncrasies of 
an individual’s immune system, this result also indicates 
an increase in cytotoxic cells at the stage of dysplasia and 
a decrease in these cells, with concomitant increase in 
inflammatory cells, in the tumour tissue. We also applied 
an approach described in [7] whereby an RNA-seq based 
metric of immune cytolytic activity was devised and 
applied to numerous cancer samples. This metric, CYT, 
is calculated as the geometric mean of two key cytolytic 
effectors: granyme A: GZMA, and perforin: PRF1. Owing 
to the matched nature of our data we were able to trace 
the change in CYT score between samples within each 
patient (Supplementary Figure S1), which again indicated 
a more pronounced increase in cytolytic activity between 
N and D (0.72 ± 0.25 s.e.m) than between N and T (−0.01 
± 0.41 s.e.m).
Figure 3: Samples are plotted according to the pathologist estimates of the percentage of immune cells within the 
macrodissected FFPE tissue (x-axis) versus the immune cell score derived computationally from the transcriptional 
profile. Linear regression lines for each tissue type are drawn separately as Linear (Tumour) or Linear (Dysplasia).
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Figure 4: Heatmap indicating the average log2 fold change in expression (yellow values) of commonly used 
immunohistochemical markers for different immune cell types, as per the left hand colour key and top-right 
legend. Marker genes (row labels) are clustered according to their expression. NvD: Normal versus Dysplasia. DvT: Dysplasia versus 
Tumour
Table 1: Immune-specific cell-types (as per analysis in Bindea et al. [5]) for which a significant 
number of genes are up-regulated, and the genes up-regulated therein
NvD DvT
Cell-type Genes Cell-type Genes
aDC LAMP3, OAS3 Macrophages MARCO, BCAT1, FN1, MSR1, SULT1C2, PCOLCE2, SCG5
B-cells BLK, KIAA0125, MS4A1, SCN3A, IGKC, SLC15A2, SPIB Neutrophils BST1, DYSF, FPR1, MME
Cytotoxic cells APBA2, GNLY, GZMA, NKG7, RUNX3 Tgd C1orf61, FEZ1
NK CD56 dim 
cells IL21R, GZMB Th1 cells DGKI, DOK5, EGFL6, GGT1
T-cells LCK, CD2, CD28, CD3D, CD3E, CD6, SH2D1A Th2 cells MB, ADCY1, PTGIS, ANK1, PHEX
TFH CXCL13, SIRPG, TOX
Th1 cells BST2, CD38, CTLA4
Abbreviations: NvD: Normal versus Dysplasia. DvT: Dysplasia versus Tumour. aDC: activated Dendritic Cell. TFH: T 
Follicular Helper cell. Th1/2: T-helper 1/2 cell. Tgd: T gamma delta cell.
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The 311 genes DE NvD and NvT but not DvT 
are significantly enriched for anterior/posterior pattern 
formation, driven by numerous homeobox (HOX) genes. 
Humans have 39 HOX genes, 26 being expressed in our 
data. Of these, a significant number are DE both NvD 
(7 genes, Fisher p: 6.8 × 10−6) and NvT (13 genes, Fisher 
p: 0.0015) and several ncRNA genes expressed antisense 
to the HOX clusters are DE NvT. HOTAIRM1, transcribed 
antisense to the HOXA cluster and believed to have a 
role in myeloid cell differentiation, is also DE NvD [8]. 
Only one HOX gene, HOXB7, is DE DvT: no more than 
is expected by chance. In every case where a HOX, or 
antisense HOX, gene is DE it is upregulated (Table 2). We 
ruled out copy number/gene dosage as the cause of these 
results by inspecting all expressed genes 2 Mb up and 
downstream of the 4 HOX clusters and finding no similar 
significant upregulation therein.
Genes that are significantly DE NvD and DvT, 
but not NvT must be dysregulated in different directions 
during the stages of disease progression. Figure 5 is a 
heatmap of the 16 genes that are significantly DE NvD 
and DvT, but not NvT, showing two clear groups: genes 
upregulated NvD then downregulated DvT, and a larger 
group dysregulated vice versa. We note the presence of 
IL36G within this 16-gene subset. As shown in Figure 5 
and Supplementary Figure S2, this gene, Interleukin-36 
gamma, is almost wholly upregulated NvD and 
downregulated DvT resulting in it not being DE in the 
NvT comparison (p.adj: 0.70).
Genes associated with malignant transformation 
of dysplasia
Genes DE DvT but not NvD are dysregulated later 
in the pathological process, as a cause or consequence 
of malignant transformation of the tissue, and are 
functionally enriched in muscle contraction, actin-
binding and cytoskeletal protein-binding. We noted that 
apical or adherens junctions (the latter form part of the 
apical junction complex) are highlighted in all subsets 
of genes that are not DE NvD (Figure 2). We observed 
that the genes encoding the key components of adherens 
junctions in both normal and cancerous epithelial cells 
(E-cadherin: CDH1, β-catenin: CTNNB1, α-catenin: 
CTNNA1, p120: CTNND1 and junction plakoglobin: JUP) 
are all significantly down-regulated NvT, except F-actin 
Table 2: Log2 fold change values (Log2FC) and multiple-testing adjusted p-values for HOX genes 
and antisense HOX genes that are significantly (values in red bold) differentially expressed in at 
least one pairwise comparison at the 1% threshold
GeneName GeneType NvD DvT NvT
Log2FC Adjusted p Log2FC Adjusted p Log2FC Adjusted p
HOXA1 protein-coding 1.66 7.04E-03 −0.26 8.26E-01 1.62 8.51E-03
HOXA4 protein-coding 1.65 1.36E-01 0.24 1.00E+00 2.33 3.73E-03
HOXA7 protein-coding 1.93 9.69E-03 0.23 9.18E-01 2.23 8.15E-04
HOXA10 protein-coding 2.21 3.25E-04 0.06 1.00E+00 2.24 3.78E-05
HOXB6 protein-coding 1.17 2.25E-01 0.81 1.15E-02 2.07 4.00E-04
HOXB7 protein-coding 0.81 5.86E-02 1.05 7.31E-03 1.86 9.84E-06
HOXC4 protein-coding 1.69 7.58E-04 0.41 3.06E-01 2.10 8.13E-08
HOXC6 protein-coding 2.90 1.53E-08 0.48 3.44E-01 3.37 5.54E-14
HOXC9 protein-coding 2.94 7.15E-05 1.01 2.09E-02 3.85 5.18E-11
HOXC10 protein-coding 1.36 1.96E-01 0.51 5.57E-01 2.14 6.24E-03
HOXC13 protein-coding 1.18 3.63E-02 0.28 7.35E-01 1.38 2.35E-03
HOXD9 protein-coding 0.88 2.21E-01 0.52 3.33E-01 1.33 3.21E-03
HOXD10 protein-coding 2.62 1.03E-08 −0.18 1.00E+00 2.65 7.18E-08
HOXC-AS5 antisense 1.76 1.35E-02 0.46 3.66E-01 2.28 1.05E-04
HOTAIRM1 antisense 1.06 2.06E-03 0.19 8.48E-01 1.25 2.70E-04
HOXD-AS2 antisense 0.85 9.79E-02 0.36 4.77E-01 1.16 3.63E-04
HOXA-AS2 antisense 0.92 4.05E-02 0.33 5.44E-01 1.16 4.90E-03
Abbreviations: NvD: Normal versus Dysplasia. DvT: Dysplasia versus Tumour. NvT: Normal versus Tumour.
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(ACTB) [9]. None were also significantly altered NvD but 
all except CDH1 were significantly downregulated DvT at 
the 10% threshold. Thus, expression of adherens junction 
components is decreased after dysplasia formation, 
indicating a potential role in malignant transformation.
Genes that are consistently altered throughout 
disease progression
Genes DE in all comparisons are consistently 
dysregulated throughout OSCC development. These 
107 are enriched for epidermal and epithelial cell 
differentiation, and keratinocyte differentiation specifically 
(Supplementary Table S7).
Genes that best distinguish normal, dysplasia 
and tumour cells
To investigate whether some genes are more 
informative for separating samples into their associated 
groups (N, D or T) we performed Principal Component 
Analysis (PCA), first using just the expressed protein-
coding genes. Biplots of each combination of PCs 
1 to 10 did not show any visual separation of groups 
(Supplementary Figure S3A). However, repeating 
the analysis including expressed non-coding genes 
(Supplementary Figure S3B) resulted in an evident 
separation of normal and tumour samples using PCs 
2 and 3, with dysplasia samples overlapping on both sides 
(Figure 6). Using the average magnitude of weighting for 
each gene across PC2 and PC3 as a gene-ranking metric, 
the top 5% (Supplementary Table S8) included 904 
protein-coding and 162 non-coding genes, were enriched 
in actin filament-based processes, actin cytoskeleton 
organization, cytoskeletal and actin binding (p.adj < 0.01).
Network analysis
All of the above analyses have highlighted non-
coding genes (Supplementary Table S3 and Supplementary 
Table S8) that may have a role in dysplasia formation and 
malignant transformation. However, there is a dearth of 
functional information about the majority of non-coding 
transcripts. To prioritise such transcripts as carcinogenic 
candidates, we created an expression correlation matrix 
for all (coding and non-coding) expressed genes in all 
Figure 5: Heatmap indicating log2 fold change (Value) for the only 16 genes that are differentially expressed in both 
the NvD and DvT, but not the NvT pairwise comparison. NvD: Normal versus Dysplasia. DvT: Dysplasia versus Tumour. NvT: 
Normal versus Tumour.
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samples. Genes with similar expression profiles likely 
have similar, or complementary, roles as part of larger 
gene regulatory networks [10]. Non-coding RNAs of 
interest can, thus, be inspected within the networks of 
significantly correlated genes and functional relevance 
inferred via a ‘guilt by association’ approach as described 
in Guttman et al, 2009 [11] (Supplementary Figure S4). 
Subnetworks with particular features can then be inspected 
as in Figure 7 where a cluster of 20 significantly 
positively correlated genes are mostly dysregulated 
early in the pathological process i.e. they are DE in the 
NvD comparison only (yellow nodes) or both NvD and 
NvT (orange nodes). Supplementary Table S9 describes 
these genes, which are significantly enriched for viral 
response, defense response and immune response. Three 
antisense non-coding genes in this network, indicated by 
parallelograms in Figure 7, are each positively correlated 
with the protein-coding (circular nodes) gene to which 
it is antisense (Supplementary Table S9). Another 
subcluster contained several brown nodes (genes DE in 
all three pairwise comparisons), one of which denotes a 
lincRNA: RP11–351J23.1 (Supplementary Figure S5). 
The genes in this subcluster are significantly enriched for 
the biological processes of epithelial development and 
Figure 6: Principal component analysis (PCA) biplot of PCs 2 and 3 using all protein-coding and non-coding genes. This 
biplot best separates the three oral sample groups: N – Normal epithelia, D – Dysplasia, and T – Tumour.
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Figure 7: A subcluster of genes that are significantly positively correlated (correlation coefficient >0.95) across all 
samples in our data. Each node represents the labelled gene. Circular nodes indicate protein-coding genes. Parallelograms denote 
antisense genes. Colours indicate differential expression (DE) or lack thereof (grey) in our pairwise comparisons: yellow genes are DE NvD 
only, orange genes are DE NvD and NvT and red genes are DE NvD, DvT and NvT.
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epithelial cell differentiation, and are all downregulated in 
the comparisons for which they are DE.
DISCUSSION
A potential confounder to our study is that the 
common recurrence of OSCC post-surgery, and posited 
theory of field cancerisation, result in debate regarding 
whether ‘normal’ oral tissue in OSCC patients is truly 
free from molecular alteration, and/or whether sufficient 
margins are taken during surgery to enable excised 
samples to actually contain ‘normal’ tissue [12]. Whilst we 
sampled from pathologist-confirmed histologically normal 
tissue as far from the diseased tissue as physically possible, 
we cannot rule out that the very nature of its origination 
in a patient with OSCC may mean that our ‘normal’ tissue 
differs in some fundamental way from that in cancer free 
patients. Systematic reviews aimed at consolidating the 
literature on OSCC transcriptomes have revealed the 
heterogeneity in reported expression profiles, caused by 
both technical and biological phenomena [13]. Despite 
this, the genes highlighted as DEGs in our study have a 
91% overlap with those listed in a systematic review of 41 
previous NvT studies in OSCC, validating our results and 
showing at least that the confounding issue of ‘normal’ 
tissue equally affects the wider body of literature on 
OSCC gene expression studies like ours [13]. We also 
note that dysplasias do not always represent an earlier 
stage of an associated OSCC, but in such cases our study 
design still investigates changes in transcriptional profiles 
between non-malignant lesions and invasive carcinoma in 
the same biological background, increasing the power to 
detect pathophysiologically relevant alterations [14].
The immune system responds to dysplasia 
development
Our results show that immune response genes are 
dysregulated early, during the development of dysplasia, 
as corroborated elsewhere [15, 16]. Furthermore, 
a significant increased in transcriptional signals 
specifically from cytotoxic effector cells were evident 
in the dysplasia compared to matched normal (Table 1). 
Despite attempts to macrodissect regions of high purity 
normal, dysplastic or tumour tissue, infiltrating immune 
cells will have inevitably been included during sampling. 
The more infiltrative these cells are, the harder to dissect 
around them and the more likely we are to observe their 
transcriptional profiles. In general the level of infiltration 
is observed to be greater, under histopathological 
examination, at the tumour than the dysplastic stage so 
we may expect stronger immune cell transcriptional 
profiles in the former. However, we cannot foresee that 
our sampling approach would produce a bias towards a 
specific cell type signature unless that cell is actually more 
present at that disease stage. Analysis of an independent 
cohort of unmatched N, D and T samples (from microarray 
study GSE30784) also supported this finding, despite the 
study design negating our ability to investigate changes in 
immune response throughout disease development within 
individual patients, where such findings will become more 
apparent. The involvement of cytotoxic cells at this early 
stage supports the concept of cancer immunosurveillance, 
which postulates that the immune system acts to identify 
and remove abnormal cells, such as dysplasia [17]. 
A significant upregulation in macrophage- and neutrophil-
specific gene expression is observed between matched 
dysplasia and tumour, and of macrophage genes DvT in 
the unmatched validation cohort, indicating the addition 
of inflammatory immune cells at the tumour stage. These 
could be the result of a more sustained immune response to 
the tumour. However, tumour-associated macrophages and 
neutrophils have also been shown to play a role in creating 
an immune-suppressive tumour microenvironment in 
many cancers including head and neck cancer [18, 19]. 
It is now believed that immunosurveillance is the first of 
a three-step process referred to as cancer immunoediting, 
in which abnormal cells are first eliminated, as indicated 
above, but with the possibility that clonal evolution results 
in cells able to survive immune attack and, following 
immune evasion, begin aberrantly proliferating [17]. 
An interesting hypothesis relating to OSCC, based 
on the concept of immunoediting, is that malignant 
transformation occurs in those dysplasia cells able to 
evade immune attack. Our experimental design cannot be 
used to test this hypothesis but previous studies in head 
and neck cancer have revealed immune suppression in 
tumour regions, and mouse models of oral carcinogenesis 
suggests that the premalignancy microenvironment 
is indeed more immune stimulatory than the OSCC 
environment [20–22]. We also did some preliminary 
testing of this hypothesis using an additional independent 
cohort (dataset GSE26549) of 86 oral dysplasias with 
clinical follow up over median 6.08 years [23]. The genes 
upregulated in the 51 dysplasia samples from patients that 
did not develop OSCC (non-progressive) versus 35 that 
did (progressive) were significantly enriched for genes 
(22 genes, FDR = 5.16 × 10−5, Supplementary Table S10) 
switched on in stimulated versus naive T cells (MSigDB 
C7: Nick Haining Lab [DFCI]). This does indicate that 
dysplasias with a heightened immune response are less 
likely to undergo malignant transformation.
Genes significantly upregulated NvD and 
downregulated DvT are candidate malignancy drivers 
and include IL36G as the only immune response gene 
(Figure 5 and Supplementary Figure S2). This gene, 
interleukin-36 gamma, is expressed in keratinocytes and 
the encoded protein may act, besides interferon gamma, 
as key signaling molecule in immunopathology as part of 
the local inflammatory response in epithelial cells [24, 25].
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HOX genes as candidate drivers of dysplasia 
formation and progression
HOX genes all encode transcription factors (TFs) 
with a conserved homeodomain (HD). First identified 
for their involvement in spatial development along 
the anteroposterior axis, they are now known to also 
participate in maintenance of tissue architecture throughout 
an organism’s lifetime [26]. Dysregulation of HOX 
genes is common in cancer and has been associated with 
oncogenesis and acquisition of a stem cell phenotype [27]. 
In agreement with our NvT results, HOX genes have 
been observed to be consistently upregulated in OSCC 
compared with normal oral mucosa [28, 29]. Our results 
further indicate that the majority of HOX upregulation 
occurs specifically during the development of dysplasia. 
We also found that a significant number of HOX genes 
(12 genes, FDR = 0.03) are upregulated in dysplasias that 
progress to OSCC versus those that do not (independent 
dataset GSE26549) further implying that HOX expression 
is associated with malignant transformation [23].
Long ncRNAs expressed antisense to HOX gene 
clusters have been shown to act as master regulators and 
also become dysregulated during cancer [30–32]. Our 
approach highlighted several antisense HOX transcripts 
as DE NvT and one, HOTAIRM1, is also significantly 
upregulated NvD (Table 2). These are worthy of further 
functional characterization in relation to the development 
and progression of OSCC.
Malignancy is associated with an invasive 
phenotype
Genes dysregulated later, during malignant 
transformation of dysplasia, are enriched in functional 
terms associated with the extracellular matrix (ECM) and 
apical or adherens junctions (Figure 2). Dysregulation 
of genes involved in ECM degradation or remodeling 
has been implicated in OSCC progression previously 
and associated with the ability of cells to begin invading 
through the basement membrane, as is characteristic 
of malignant transformation [33, 34]. Apical junction 
complex (AJC) are epithelial cell-cell adhesion structures 
responsible for cell polarity and maintenance of tissue 
structure [35]. Our data shows a down-regulation of AJC 
components, most evident DvT. Overexpression of these 
components can inhibit malignant progression in oral 
cancer, in agreement with our results [36, 37].
Enrichment in processes involving actin-filaments 
and the cytoskeleton were also seen in the genes most 
informative for separating N, D and T in the PCA. This fits 
with the largest visible changes in the morphology of these 
sample types, where disorder in the cellular architecture and 
orientation, as well as evidence of invasion, are used during 
histopathological diagnosis. Of interest with the PCA is the 
almost total separation of N and T but partial overlap of 
D with both groups (Figure 6). Further longitudinal work 
is warranted, aimed at similarly clustering non OSCC-
associated dysplasia samples in these plots and seeing 
whether, prospectively, those that group with tumour 
samples have worse prognosis than those that group with 
normal oral mucosa. It would then be possible to see whether 
expression changes of adherens junction components are 
potential prognostic markers for oral dysplasia.
Non-coding genes are carcinogenic candidates
Our PCA shows separation of biologically relevant 
groups is best achieved when ncRNA expression is 
included (Supplementary Figure S3). We have attempted 
to highlight non-coding genes that are carcinogenic 
candidates in a more functionally relevant way using 
network analysis. Here we have discovered several 
ncRNAs that are significantly correlated with protein 
coding genes in small subclusters that are dysregulated 
at different points in the pathological process. One such 
cluster is dysregulated early during development of 
dysplasia i.e. NvD (Figure 7) and independently displays 
the same enrichment in immune response that the whole 
list of genes that are DE at this stage exhibit. Within 
this subcluster are several antisense genes of unknown 
function, each directly correlating with the protein-coding 
gene to which is it antisense. Our alignment statistics 
show high (96 ± 3%, Supplementary Table S2) strand 
specificity, ensuring these results are not an artifact of 
reduced strandedness in our data. Also, RP11-638I2.8 
shares no exonic bases with the WARS gene to which it 
is antisense, instilling confidence in the validity of our 
results. These ncRNAs are candidate regulators of this 
sub-cluster. Likewise, lincRNA, RP11-351J23.1 is in a 
subcluster of genes dysregulated mostly during malignant 
transformation and so should be further functionally 
characterized (Supplementary Figure S5).
Further work
This is the largest gene expression study of its kind, 
but the nature of the samples (FFPE tissue from surgeries 
where patients had normal oral epithelium, dysplasia and 
tumour excised) meant the majority of tissue was required 
as input for sequencing libraries. This left us unable to 
systematically validate our findings at the protein level, 
especially as proteomics studies using FFPE samples 
are notoriously difficult owing to the cross-linking that 
occurs during fixation [38]. The hope is that unbiased, 
systematic studies such as ours highlight new avenues for 
more focused research into potentially interesting disease 
mechanisms that are highlighted as occurring at specific 
disease stages. Examples of this would be a study testing 
the hypothesis that adherens junctions are diminished in 
OSCC versus oral dysplasia using tissue microarrays, as 
has been performed in cervical neoplasias [39].
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It is highly desirable to find ways of treating oral 
dysplasia to either eradicate it, without requiring extensive 
surgeries that often detrimentally affect the patient’s life 
quality, or prevent its malignant transformation. This 
study highlights several coding and non-coding genes as 
candidates in the development and progression of oral 
dysplasia. Whilst further basic science research is required 
to validate findings at the protein and/or mechanistic level, 
we can speculate how our findings may be pursued in the 
context of translational research.
Could oncolytic viruses prevent immune evasion by 
dysplasia?
Oncolytic viruses target and kill tumour cells, 
either directly or by triggering a novel or increased host 
anti-tumour immune response [40, 41]. The latter is 
potentially relevant to the treatment of oral dysplasia: 
using oncolytic viruses to boost the host immune 
response to dysplastic cells, aiming to eradicate them 
before they can evade the immune system and potentially 
undergo subsequent malignant transformation. Other 
immunotherapy approaches could equally be beneficial, 
but these often include immune checkpoint blockades; 
oncolytic viruses may be more applicable to oral dysplasia, 
where malignant transformation is not inevitable, because 
they are much less toxic and could be applied topically 
rather than systemically. In support of this, a modified 
adenovirus, ONYX-015, has previously been applied to oral 
dysplasia with some success [42]. Our results suggest the 
potential for further translational research into a) whether 
immune evasion is part of malignant transformation and, if 
so, b) the use of oncolytic viruses known to heighten anti-
tumour immunity in the treatment of oral dysplasia.
Are HOX gene products druggable targets in 
dysplasia?
The functional activity of HOX gene products 
requires their association with a co-factor: PBX. This 
interaction can be blocked by small peptide inhibitor 
HXR9, leading to global repression of HOX gene 
function [43]. HRX9 has been shown to induce apoptosis 
of tumour cells, and reduce tumour growth, when applied 
to cell-lines derived from breast, ovarian, renal, prostate 
and non-small-cell lung cancers [43–47]. Our results 
indicate that upregulation of HOX gene expression is an 
early event in the development of dysplasia in the oral 
cavity and, if this result is confirmed at the protein level, 
application of HOX inhibitors to dysplasia may have 
therapeutic benefit. This hypothesis can be tested using 
the commercially available HRX9 molecule.
In conclusion, our results have highlighted several 
novel mechanisms and specific candidates for further 
basic scientific work on functional characterization. 
This includes, but is not limited to, the potential roles 
of immunoediting, and specifically IL36G, and adherens 
junction components in malignant transformation, and the 
role of lincRNA RP11-351J23.1 in de-differentiation of 
OSCCs.
MATERIALS AND METHODS
More detail regarding methods, and references to 
software, are in the Supplementary Document.
Patient selection
Leeds General Infirmary OSCC patients fulfilling 
the following criteria were selected and consented: (i) first 
diagnosis of OSCC, (ii) untreated prior to surgery, (iv) normal 
and dysplastic epithelium and tumour present in their surgical 
sample and (v) clinical diagnosis of HPV negative tumour 
(subsequently confirmed via RNA analysis, see supplemental 
document). Formalin-fixed paraffin-embedded (FFPE) 
blocks of surgical sample were the used in this study after 
a pathologist identified the most representative blocks from 
which to source each sample type. Patient details are given in 
Supplementary Table S1. Study ethical codes: REC numbers 
07/Q1206/30 and 08/H1306/127.
RNA extraction
H&E stained FFPE sections underwent an 
independent, blind, diagnostic pathology review with 
concurrent marking of specific tissue regions (normal 
epithelium, dysplastic epithelium and cancer – Figure 1). 
Non-adjacent areas were selected, and different slides 
used, for each tissue type wherever possible. Consecutive 
unstained sections, used for RNA extraction, were heated 
at 60°C for 3 min, then rehydrated by immersion in xylene 
for 5 min, 100% ethanol for 5 min, 90% ethanol for 5 min, 
70% ethanol for 5 min. Sections were immediately macro-
dissected, as per pathologist annotation, using sterile 
disposable scalpels and tissue placed in a sterile centrifuge 
tube labelled with patient and sample ID. Total RNA was 
extracted from macro-dissected tissue using the High Pure 
FFPE RNA Micro kit according to the manufacturer’s 
instructions (Roche, Burgess Hill, West Sussex, UK) 
and quantified and quality checked using a Nanodrop™ 
8000 (Thermo Fisher scientific Ltd, Altrincham, Cheshire, 
UK), a 2200 TapeStation (Agilent Technologies UK 
Ltd, Wokingham, Berkshire, UK) and the Quant-it™ 
RNA BR Assay kit for the Qubit® 2.0 Fluorometer (Life 
Technologies Ltd, Paisley, UK).
Library preparation
Strand-directional whole transcriptome sequencing 
libraries were prepared using the ScriptSeq™ Complete 
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Kit (Human/Mouse/Rat)-Low Input (Epicentre, Madison, 
Wisconsin, USA) as per instructions for FFPE samples. 
The Ampure XP system (BeckmanCoulter) was used for 
clean-up steps where recommended. Purified Libraries 
were quality checked and quantified on a 2200 Tapestation 
using a D1000 screen tape. Samples with >10% adapter 
contamination were subject to repeat purification using the 
Ampure XP system.
Sequencing and alignment
100bp paired-end sequencing was performed on 
a HiSeq2500. Fastq files were processed using Trim 
Galore! version 0.2.7, to remove low quality bases, trim 
adaptors and fix paired-end reads, retaining unpaired 
reads of at least 35bp post-trimming. Reads were aligned 
in a strand directional manner to human reference 
genome GRCh37.p11, using the gencode.v17 genome 
annotation as a guide, using Tophat2, version 2.0.7. 
Reads were allowed to align a maximum of five times 
with maximum two mismatches. Alignment statistics are 
given in Supplementary Table S2.
HPV analysis
To confirm HPV status, reads were aligned to 
the HPV16 and HPV18 genomes using Tophat2. As a 
positive control we also aligned RNAseq data from a 
HPV positive patient’s trio of samples to these genomes. 
Zero reads aligned to HPV18 in all cases. The number 
of reads aligning to HPV16 was zero in all samples 
from all patients included in this study except PG137 
for which there were 7 reads and 4 reads that aligned in 
the N and T samples respectively. In contrast, the HPV 
positive patient had zero aligned in their N sample and 
4210 and 1137 reads aligning in their D and T samples 
respectively.
Expression quantification
Cuffdiff gave Fragments Per Kilobase per million 
reads Mapped (FPKM) and count data (denoted raw_frags) 
for each sample, after assigning multireads to their most 
probably location. Genes with average FPKM ≥ 0.1 across 
all samples of a tissue type were classed as ‘expressed’ 
and included in downstream analysis (see Supplemental 
Document for justification).
Differential expression analysis
EdgeR was used for differential expression analysis 
because it can be applied in paired mode. Three pairwise 
comparisons were made: normal epithelium versus 
dysplasia (NvD), dysplasia versus tumour (DvT) and 
normal epithelium versus tumour (NvT). A false discovery 
rate of 0.01 was used.
Functional enrichment
The David Bioinformatics Database 6.7 assessed 
functional enrichment, using all 29,733 expressed genes 
as the background from which to measure enrichment. 
Individual lists of significantly differentially expressed 
genes were input as per the details in the results section, for 
which the findings are described and tabulated in Figure 2. 
Gene ontology terms were inspected, and pathway analysis 
using Biocarta, KEGG and Panther with the latter also 
used to indicate gene family enrichment. A Benjamini-
Hochberg corrected p-value <0.05 was significant.
Heatmaps, boxplots and principal component 
analysis (PCA)
Heatmaps and boxplots were created in R using the 
gplots. heatmap.2 and boxplot functions respectively. PCA 
was performed for (i) all expressed genes, and (ii) expressed 
protein-coding genes, using the R prcomp function. The 
gene weightings for the biplot axes that best separated 
tissue types were acquired from the rotation matrices and 
averaged to create a ranking, with an R script additionally 
annotating DE genes (Supplementary Table S3).
Correlation and network creation
Expressed genes were correlated against one 
another, as previously described [48]. To ascertain the 
threshold of significance, 1% of the correlations (~4.42 
× 106 values) were selected at random and the correlation 
values that demarcated the top and bottom 0.0005% were 
calculated: -0.74 and 0.95. Correlations equal to or outside 
these thresholds were retained. The resulting network 
was plotted using Cytoscape v3.0.2, with annotation files 
indicating, per gene, the type of gene and whether, and 
between which pairwise comparisons, it was DE.
Immune cell analysis
The pathologist (JG) provided a visual estimation 
of the immune and tumour cell percentage within the 
annotated/extracted regions of FFPE sections using 
a light microscope, as is standard practice in clinical 
diagnosis. Computational quantification was done using 
the ESTIMATE programme with expressed gene FPKM 
values for all samples as input. The output was an 
immune score per sample. Immune-cell specific genes 
were extracted from the Supplementary Material of 
Bindea et al [5]. The number of significantly (p < = 0.01) 
upregulated genes of each immune cell type was compared 
to the total number of significantly upregulated genes, in 
the NvD and DvT analyses separately. A Fisher’s test 
(p < = 0.05) was used to identify immune cell types for 
which a significant number of genes had been upregulated 
in either analysis. The CYT scores were calculated as the 
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geometric mean (log2 of the average) of expression, in 
FPKM, of GZMA and PRF1 as devised in [7].
Independent dataset validation
We used two datasets to validate our findings, 
where possible. GSE30784 consists of Affymetrix U133 
2.0 Plus GeneChip microarray expression data from 45 
normal oral samples, 17 oral dysplasias and 167 oral 
carcinomas (HPV status not indicated) from different 
individuals [33]. The quality of data from each microarray 
was assessed, and confirmed, by downloading the raw 
.CEL file data from the Gene Expression Omnibus (GEO) 
and running the AffyQCReport package in R. Expression 
values, normalized and background corrected using the 
gcRMA package in R, were then downloaded from the 
Gene Expression Omnibus (GEO) and collapsed into 
gene expression values using the collapseRows package 
in R with ‘MaxMean’ function [49]. Pairwise differential 
gene expression analysis was performed using the limma 
package with an adjusted p-value significance threshold of 
0.05. Fisher tests were then used to compare the number 
of DEGs in each immune cell category, according to 
the Bindea et al [5] classification, in the NvD and DvT 
comparisons. GSE26549 consists of Affymetrix Human 
Gene 1.0 ST microarray expression from 86 patients with 
oral dysplasia, of which 35 developed oral cancer over a 
median follow up of 6.08 years [23]. We refer to the two 
groups within these data as dysplasias that progressed and 
those that did not. The accompanying publication for this 
dataset included lists of genes that are DE between the two 
groups, and their direction of dysregulation. These lists 
were downloaded and functional enrichment in different 
subsets were evaluated using ToppFun [50].
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